Patents by Inventor Xiangtian Zhou

Xiangtian Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • APPLICATION OF REGULATION OF EYE SCLERA LIPID METABOLISM TO INHIBIT MYOPIA
    Publication number: 20230321023
    Abstract: The present invention relates to an application of inhibiting myopia by regulating eye scleral lipid metabolism. The present discloses a new mechanism leading to myopia, i.e., a close relationship between abnormal eye scleral lipid metabolism and myopia, thus revealing a new target for prevention and control of myopia; meanwhile, also provided is an eye drop that can effectively prevent and control myopia while avoiding eye allergies.
    Type: Application
    Filed: September 14, 2021
    Publication date: October 12, 2023
    Applicant: Wenzhou Medical University
    Inventors: Xiangtian ZHOU, Miaozhen PAN, Fei ZHAO, Jia QU
  • METHOD FOR TREATING MYOPIA AND APPLICATION IN PREPARATION OF MEDICAMENT
    Publication number: 20220016023
    Abstract: A method for inhibiting extension of an ocular axis, wherein the extension of the ocular axis is inhibited by a manner of increasing the volume of choroidal blood flow. The method may include expanding choroidal vessels by using drugs, including locally administering a drug increasing the volume of choroidal blood flow to an eye.
    Type: Application
    Filed: September 30, 2021
    Publication date: January 20, 2022
    Inventors: Xiangtian ZHOU, Sen ZHANG, Jia QU, Guoyun ZHANG, Fei ZHAO, Xuan ZHOU
  • METHOD FOR INHIBITING MYOPIA AND APPLICATION IN PREPARING DRUG
    Publication number: 20200121706
    Abstract: A method for inhibiting myopia and an application in preparing a drug. According to the invention, myopia is inhibited by an anti-hypoxia effect achieved by inhibiting the expression of intraocular HIF-1?, and myopia is effectively delayed and inhibited by an anti-hypoxia effect achieved by inhibiting the effect of intraocular HIF-1?. The present invention utilizes HIF-1? inhibitors salidroside and formononetin to inhibit HIF-1? activity to play an anti-hypoxia effect and play a role in delaying myopia.
    Type: Application
    Filed: August 16, 2017
    Publication date: April 23, 2020
    Inventors: Jia QU, Fei ZHAO, Xiangtian ZHOU, Miaozhen PAN, Sen ZHANG, Qingyi ZHOU, Hao WU
  • METHOD FOR TREATING MYOPIA AND APPLICATION IN PREPARATION OF MEDICAMENT
    Publication number: 20200022908
    Abstract: A method for treating myopia and an application in preparation of a medicament are provided, where the volume of choroidal blood flow is increased by expanding the choroid via a drug or a surgical method, so as to achieve treatment of the myopia caused by scleral hypoxia, which provides a new idea and method for treating myopia.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 23, 2020
    Inventors: Xiangtian ZHOU, Sen ZHANG, Jia QU, Guoyun ZHANG, Fei ZHAO, Xuan ZHOU
  • Method of inhibiting myopia and application of an adenylyl cyclase inhibitor as a drug for inhibiting myopia
    Patent number: 9084791
    Abstract: Methods for inhibiting myopia are disclosed. A method for inhibiting myopia includes reducing a level of an intraocular cAMP in a subject. The level of the intraocular cAMP is reduced by injecting an adenylyl cyclase inhibitor to achieve the inhibition of myopia in the subject. In one method, the adenylyl cyclase inhibitor is SQ22536.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: July 21, 2015
    Assignee: SCHOOL OF OPHTHALMOLOGY AND OPTOMETRY, WENZHOU MEDICAL COLLEGE
    Inventors: Xiangtian Zhou, Jia Qu, Yijin Tao, Miaozhen Pan
  • Method Of Inhibiting Myopia And Application Of An Adenylyl Cyclase Inhibitor As A Drug For inhibiting Myopia
    Publication number: 20120270887
    Abstract: Methods for inhibiting myopia are disclosed. A method for inhibiting myopia includes reducing a level of an intraocular cAMP in a subject. The level of the intraocular cAMP is reduced by injecting an adenylyl cyclase inhibitor to achieve the inhibition of myopia in the subject. In one method, the adenylyl cyclase inhibitor is SQ22536.
    Type: Application
    Filed: December 21, 2011
    Publication date: October 25, 2012
    Applicant: SCHOOL OF OPHTHALMOLOGY AND OPTOMETRY, WENZHOU MEDICAL COLLEGE
    Inventors: Xiangtian Zhou, Jia Qu, Yijin Tao, Miaozhen Pan